➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: October 16, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022239

Email this page to a colleague

« Back to Dashboard

NDA 022239 describes SUMAVEL DOSEPRO, which is a drug marketed by Endo Ventures Ltd and is included in one NDA. There are nine patents protecting this drug. Additional details are available on the SUMAVEL DOSEPRO profile page.

The generic ingredient in SUMAVEL DOSEPRO is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
Summary for 022239
Applicant:Endo Ventures Ltd
Ingredient:sumatriptan succinate
Formulation / Manufacturing:see details

Profile for product number 001

Approval Date:Jul 15, 2009TE:RLD:Yes
Patent:⤷  Free Forever TrialPatent Expiration:Nov 22, 2026Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Free Forever TrialPatent Expiration:Jul 31, 2026Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Free Forever TrialPatent Expiration:Aug 10, 2023Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 022239

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.